Home

Michael F MacLean

CIK 1383731 · Chief Financial Officer · last filed 2026-04-03

Michael F MacLean is a Chief Financial Officer who has filed 59 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for CAMP, was dated Apr 3, 2026. Across all open-market trades the lifetime net is −$16.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.0M across reported positions. 22 SEC filings were submitted jointly with BIOGEN INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.96M

Companies

6

Total Filings

59

Lifetime Open-Market Net

-$16.65M

Filer Profile

Reported Address
C/O AVIDITY BIOSCIENCES, INC.
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO, CA 92121
Related Filers
BIOGEN INC. — 22 joint filings, latest 2010-10-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CAMP Director — $4.25 — $0 1 2026-04-03
Avidity Biosciences, Inc. (RNAM) Delisted Chief Financial Officer 0 — — $0 1 2026-02-27
RNA Chief Financial Officer 62,025 $10.36 $642.6K -$15.13M 18 2026-01-23
Verve Therapeutics, Inc. (VERV) Delisted Director — $11.13 — $0 7 2025-07-28
AKCEA THERAPEUTICS, INC. (AKCA) Delisted Chief Financial Officer 48,000 — — $0 6 2020-01-16
BIIB SVP, Chief Accounting Officer 10,681 $217.15 $2.32M -$1.52M 21 2010-10-04

Recent Filings

59 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-03 CAMP Grant (A) — $0 EDGAR
2026-02-27 Avidity Biosciences, Inc. (RNAM) Delisted Disp (D) −133,977 $0 EDGAR
2026-01-23 RNA Sell (S) −4,542 -$329.1K EDGAR
2026-01-09 RNA Sell (S) −1,974 -$142.6K EDGAR
2025-08-15 RNA Sell (S) −30,914 -$1.32M EDGAR
2025-08-06 Avidity Biosciences, Inc. (RNAM) Delisted Notice (144) −30,914 -$1.18M EDGAR
2025-07-28 Verve Therapeutics, Inc. (VERV) Delisted Disp (D) — $0 EDGAR
2025-06-06 Verve Therapeutics, Inc. (VERV) Delisted Grant (A) — $0 EDGAR
2025-03-21 RNA Sell (S) −7,935 -$246.4K EDGAR
2025-01-23 RNA Sell (S) −3,287 -$94.0K EDGAR
Showing 1–10 of 59
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.